Hengrui Medicine announces HK IPO price at HKD 44.05 per share
Jiangsu Hengrui Medicine (SSE:600276) announced the final offering price for its overseas-listed foreign shares (H shares) at HKD 44.05 per share. This price excludes a 1% brokerage commission, a 0.0027% Securities and Futures Commission transaction levy, a 0.00565% Hong Kong Stock Exchange trading fee, and a 0.00015% Financial Reporting Council transaction levy. Trading of the H shares on the Main Board of the Hong Kong Stock Exchange is expected to commence on May 23, 2025. The offering targets qualified overseas investors and eligible domestic institutions managing overseas securities investments. The company emphasized that this announcement is solely for the information of A-share investors and does not constitute an offer or solicitation to any individual or entity.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime